Dr Rifkin on the Efficacy and Safety of the Dreamm-7 Trial in R/R Myeloma

Robert M. Rifkin, MD, FACP, medical oncologist, hematologist, Rocky Mountain Cancer Centers, discusses overall survival analysis and efficacy outcomes from the phase 3 Dreamm-7 trial (NCT04246047) in patients with relapsed/refractory multiple myeloma. Rifkin and colleagues shared this data in a presentation at the 2024 ASH Annual Meeting.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Multiple Myeloma

BMS-22-OSD1240 - /clinical/multiple-myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


ASH Annual Meeting and Exposition

Robert M. Rifkin, MD, FACP, discusses the safety and efficacy of the phase 3 Dreamm-7 trial in patients with relapsed/refractory multiple myeloma.

Dr Rifkin on Efficacy and Safety Data From the Dreamm-7 Trial in R/R Myeloma